View Agent
| Agent Info | |
| Agent: | BGT226 |
| Synonyms: | NA |
| Drug Status For Certain Diseases: | phase I/II(Solid tumours) |
| Classification: | oral phosphatidylinositol-3-kinase and mTOR inhibitor |
| Target: | PI3K gamma Serine/threonine-protein kinase mTOR |
| KEGG Pathway: | HIF-1 signaling pathway Acute myeloid leukemia Type II diabetes mellitus Glioma Central carbon metabolism in cancer Adipocytokine signaling pathway Choline metabolism in cancer Insulin signaling pathway AMPK signaling pathway MicroRNAs in cancer mTOR signaling pathway PI3K-Akt signaling pathway Thyroid hormone signaling pathway Pathways in cancer Prostate cancer |
| Wiki Pathway: | GPVI-mediated activation cascade Regulation of toll-like receptor signaling pathway AMPK Signaling Interferon type I signaling pathways Polycystic Kidney Disease Pathway Prostate Cancer Integrated Breast Cancer Pathway TOR Signaling EPO Receptor Signaling B Cell Receptor Signaling Pathway GPCR downstream signaling Wnt Signaling Pathway Netpath Extracellular vesicle-mediated signaling in recipient cells FSH signaling pathway Signaling by Insulin receptor Focal Adhesion MicroRNAs in cardiomyocyte hypertrophy IL-5 Signaling Pathway Alpha 6 Beta 4 signaling pathway TSLP Signaling Pathway Leptin signaling pathway Toll-like receptor signaling pathway Regulation of Actin Cytoskeleton Insulin Signaling Senescence and Autophagy in Cancer Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) PIP3 activates AKT signaling Signaling Pathways in Glioblastoma EGF/EGFR Signaling Pathway BDNF signaling pathway TSH signaling pathway RANKL/RANK Signaling Pathway Costimulation by the CD28 family Type II diabetes mellitus PI Metabolism ErbB Signaling Pathway SREBP signalling DNA Damage Response (only ATM dependent) Cardiac Hypertrophic Response Oncostatin M Signaling Pathway SREBF and miR33 in cholesterol and lipid homeostasis |